The Company

Ranbaxy Italia S.p.A. is a wholly owned subsidiary of Ranbaxy Laboratories Limited, India’s largest pharmaceutical company. Ranbaxy is one of the top ten generic pharmaceutical companies worldwide, and it is at the forefront projecting the strategic advantages of India to the developed and developing world. Established in the early 1960s, driven by application and determination, Ranbaxy has grown to become one of the most important protagonists of the international pharmaceutical industry, with manufacturing plants in 7 countries, ground operations in 46 countries and with sales in 125 countries worldwide. And now Italy is included in this presence. In Italy it is now possible benefit from very high quality active ingredients and medicines relied on throughout the world. Thanks to significant investment in research and development in recent years, Ranbaxy has successfully developed treatments to counter the challenges coming from different therapeutic areas. Whilst remaining linked to its tradition of generic medicines and active ingredients producer, Ranbaxy has complemented its portfolio with innovative products, allowing it to distinguish itself in different sectors, both in the ethical sector and in the OTC sector (in this last field the Company in expanding through strategic alliances and acquisitions).

Our Address

Ranbaxy Italia SpA
Legal office: Piazza Meda, 3 20121 Milano.
Operative office: Ariberto, 3 20123 Milano.
Tel: +39 02 89415758 Int.200
Fax: +39 02 89419546
To contact us, you can write at the e-mail address info.italia@ranbaxy.com

Ranbaxy in the world

Fundamental in the path that has seen grow Ranbaxy, has been the entry into the markets in the United States and in Europe, which is forecast to represent 50% of the Company’s sales. The most important overseas market is the United States, among the most competitive and developed pharmaceutical markets in the world, where Ranbaxy is present with more than 100 products. The Company also has a presence across Europe, with subsidiaries in the United Kingdom, Germany, France (with the acquisition of the Generic division of Aventis), Spain, Portugal, Poland and Romania. Ranbaxy also has sales across Northern, Central and Eastern Europe through distribution and co-marketing agreements. Ranbaxy also has operations in other key-markets such as Brazil and Latin America, China, Japan, Malaysia, Russia, Ukraine, Egypt and South Africa (to name a selection). This world-wide presence demonstrates tangible evidence of the value that Ranbaxy attaches to operating at an international level. Ranbaxy manufactures to the highest international standards to give the best pharmaceutical products and the best services.